Trial Profile
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Lenalidomide
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 May 2010 New trial record